|
Real-time Estimate
Cboe Europe
15:21:30 20/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 72.80 CHF | +0.14% |
|
+0.41% | +33.46% |
Company Valuation: Basilea Pharmaceutica AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 484.7 | 545.8 | 422.9 | 501.2 | 672.1 | 903.4 | - | - |
| Change | - | 12.62% | -22.52% | 18.52% | 34.1% | 34.4% | - | - |
| Enterprise Value (EV) 1 | 552.8 | 630 | 473.9 | 472.6 | 585.2 | 736.1 | 673.2 | 641.8 |
| Change | - | 13.97% | -24.78% | -0.28% | 23.84% | 25.78% | -8.55% | -4.66% |
| P/E | -70.6x | 44.9x | 41x | 7.09x | 17.4x | 11.2x | 15.4x | 48.8x |
| PBR | - | - | -42.3x | 6.17x | 5.26x | 4.43x | 3.3x | 3.28x |
| PEG | - | -0x | -2.6x | 0x | -0.4x | 0x | -0.6x | -0.7x |
| Capitalization / Revenue | 3.27x | 3.69x | 2.68x | 2.4x | 2.89x | 3.07x | 3.19x | 4.4x |
| EV / Revenue | 3.73x | 4.26x | 3.01x | 2.27x | 2.52x | 2.5x | 2.38x | 3.13x |
| EV / EBITDA | 287x | 32.1x | 22.8x | 7.51x | 11x | 7.48x | 10.2x | 33.1x |
| EV / EBIT | 461x | 34.1x | 24.7x | 7.72x | 11.4x | 6.36x | 10.1x | 37.9x |
| EV / FCF | -16.8x | 168x | 35.9x | 6.51x | 9.88x | 8.66x | 11.7x | 48.6x |
| FCF Yield | -5.94% | 0.6% | 2.79% | 15.4% | 10.1% | 11.5% | 8.53% | 2.06% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.58 | 1.02 | 0.86 | 5.83 | 3.14 | 6.491 | 4.73 | 1.489 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 148.1 | 147.8 | 157.6 | 208.5 | 232.4 | 294.1 | 283.1 | 205.3 |
| EBITDA 1 | 1.926 | 19.64 | 20.78 | 62.91 | 53.36 | 98.42 | 66.17 | 19.36 |
| EBIT 1 | 1.2 | 18.5 | 19.2 | 61.2 | 51.5 | 115.8 | 66.41 | 16.92 |
| Net income 1 | -6.8 | 12.15 | 10.5 | 77.6 | 40.2 | 111.3 | 74.91 | - |
| Net Debt 1 | 68.1 | 84.17 | 50.98 | -28.65 | -86.9 | -167.3 | -230.2 | -261.6 |
| Reference price 2 | 40.92 | 45.80 | 35.30 | 41.35 | 54.70 | 72.70 | 72.70 | 72.70 |
| Nbr of stocks (in thousands) | 11,844 | 11,918 | 11,980 | 12,121 | 12,288 | 12,426 | - | - |
| Announcement Date | 15/02/22 | 14/02/23 | 13/02/24 | 18/02/25 | 17/02/26 | - | - | - |
1CHF in Million2CHF
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 11.2x | 2.5x | 7.48x | -.--% | 1.07B | ||
| 17.12x | 6.54x | 12.53x | 1.74% | 65.42B | ||
| 31.85x | 8.5x | 28.11x | 0.07% | 58.91B | ||
| 38.62x | 6.88x | 20.55x | 0.84% | 55.24B | ||
| 41.79x | 5.95x | 28.33x | -.--% | 45.66B | ||
| 32.7x | 3.15x | 13.61x | -.--% | 41.29B | ||
| 36.32x | 8.98x | 23.42x | 0.36% | 36.82B | ||
| -18.89x | 54.48x | -20.65x | -.--% | 34.48B | ||
| 41.53x | 8.01x | 26.87x | -.--% | 32.5B | ||
| -89.49x | 16.75x | -96.22x | -.--% | 31.69B | ||
| Average | 14.28x | 12.17x | 4.40x | 0.3% | 40B | |
| Weighted average by Cap. | 18.85x | 11.69x | 8.55x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BSLN Stock
- Valuation Basilea Pharmaceutica AG
Select your edition
All financial news and data tailored to specific country editions
















